{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Chinese herbal medicine", "IL-33", "allergic inflammation", "eosinophils", "innate lymphoid cells (ILC)", "mast cells", "signal transduction", "therapeutics"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30886621", "DateCompleted": {"Year": "2020", "Month": "09", "Day": "02"}, "DateRevised": {"Year": "2020", "Month": "09", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "03", "Day": "04"}], "Language": ["eng"], "ELocationID": ["364", "10.3389/fimmu.2019.00364"], "Journal": {"ISSN": "1664-3224", "JournalIssue": {"Volume": "10", "PubDate": {"Year": "2019"}}, "Title": "Frontiers in immunology", "ISOAbbreviation": "Front Immunol"}, "ArticleTitle": "IL33: Roles in Allergic Inflammation and Therapeutic Perspectives.", "Pagination": {"StartPage": "364", "MedlinePgn": "364"}, "Abstract": {"AbstractText": ["Interleukin (IL)-33 belongs to IL-1 cytokine family which is constitutively produced from the structural and lining cells including fibroblasts, endothelial cells, and epithelial cells of skin, gastrointestinal tract, and lungs that are exposed to the environment. Different from most cytokines that are actively secreted from cells, nuclear cytokine IL-33 is passively released during cell necrosis or when tissues are damaged, suggesting that it may function as an alarmin that alerts the immune system after endothelial or epithelial cell damage during infection, physical stress, or trauma. IL-33 plays important roles in type-2 innate immunity via activation of allergic inflammation-related eosinophils, basophils, mast cells, macrophages, and group 2 innate lymphoid cells (ILC2s) through its receptor ST2. In this review, we focus on the recent advances of the underlying intercellular and intracellular mechanisms by which IL-33 can regulate the allergic inflammation in various allergic diseases including allergic asthma and atopic dermatitis. The future pharmacological strategy and application of traditional Chinese medicines targeting the IL-33/ST2 axis for anti-inflammatory therapy of allergic diseases were also discussed."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong."}], "LastName": "Chan", "ForeName": "Ben C L", "Initials": "BCL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau."}], "LastName": "Lam", "ForeName": "Christopher W K", "Initials": "CWK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong."}], "LastName": "Tam", "ForeName": "Lai-Shan", "Initials": "LS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong."}, {"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong."}], "LastName": "Wong", "ForeName": "Chun K", "Initials": "CK"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Immunol", "NlmUniqueID": "101560960", "ISSNLinking": "1664-3224"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "IL1RL1 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "IL33 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-1 Receptor-Like 1 Protein"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-33"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["immunology", "pathology", "therapy"], "DescriptorName": "Hypersensitivity"}, {"QualifierName": [], "DescriptorName": "Immunity, Innate"}, {"QualifierName": ["immunology", "pathology", "therapy"], "DescriptorName": "Inflammation"}, {"QualifierName": ["immunology"], "DescriptorName": "Interleukin-1 Receptor-Like 1 Protein"}, {"QualifierName": ["immunology"], "DescriptorName": "Interleukin-33"}, {"QualifierName": ["immunology", "pathology"], "DescriptorName": "Leukocytes"}, {"QualifierName": [], "DescriptorName": "Medicine, Chinese Traditional"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. . IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. (2005) 23:479\u201390. 10.1016/j.immuni.2005.09.015", "ArticleIdList": ["10.1016/j.immuni.2005.09.015", "16286016"]}, {"Citation": "Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE. (2008) 3:e3331. 10.1371/journal.pone.0003331", "ArticleIdList": ["10.1371/journal.pone.0003331", "PMC2556082", "18836528"]}, {"Citation": "Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. . IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. (2007) 104:282\u20137. 10.1073/pnas.0606854104", "ArticleIdList": ["10.1073/pnas.0606854104", "PMC1765450", "17185418"]}, {"Citation": "Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol. (2009) 30:227\u201333. 10.1016/j.it.2009.03.003", "ArticleIdList": ["10.1016/j.it.2009.03.003", "19359217"]}, {"Citation": "Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. (2009) 106:9021\u20136. 10.1073/pnas.0812690106", "ArticleIdList": ["10.1073/pnas.0812690106", "PMC2690027", "19439663"]}, {"Citation": "Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. (2014) 31:31\u20137. 10.1016/j.coi.2014.09.004", "ArticleIdList": ["10.1016/j.coi.2014.09.004", "25278425"]}, {"Citation": "Cayrol C, Girard JP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. (2018) 281:154\u201368. 10.1111/imr.12619", "ArticleIdList": ["10.1111/imr.12619", "29247993"]}, {"Citation": "Xu D, Chan WL, Leung BP, Huang F, Wheeler R, Piedrafita D, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. (1998) 187:787\u201394.", "ArticleIdList": ["PMC2212173", "9480988"]}, {"Citation": "Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, et al. . The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science. (2012) 335:984\u20139. 10.1126/science.1215418", "ArticleIdList": ["10.1126/science.1215418", "22323740"]}, {"Citation": "Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol. (1998) 161:4866\u201374.", "ArticleIdList": ["9794420"]}, {"Citation": "Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. . Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. (2010) 463:540\u20134. 10.1038/nature08636", "ArticleIdList": ["10.1038/nature08636", "20023630"]}, {"Citation": "Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. . Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. (2010) 464:1367\u201370. 10.1038/nature08900", "ArticleIdList": ["10.1038/nature08900", "PMC2862165", "20200518"]}, {"Citation": "Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al. . Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA. (2010) 107:11489\u201394. 10.1073/pnas.1003988107", "ArticleIdList": ["10.1073/pnas.1003988107", "PMC2895098", "20534524"]}, {"Citation": "Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. (2009) 123:1047\u201354. 10.1016/j.jaci.2009.02.026", "ArticleIdList": ["10.1016/j.jaci.2009.02.026", "PMC2711963", "19361843"]}, {"Citation": "Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood. (2009) 113:1526\u201334. 10.1182/blood-2008-05-157818", "ArticleIdList": ["10.1182/blood-2008-05-157818", "PMC2644080", "18955562"]}, {"Citation": "Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al. . The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol. (2009) 39:1046\u201355. 10.1002/eji.200838575", "ArticleIdList": ["10.1002/eji.200838575", "19266498"]}, {"Citation": "Nabekura T, Girard JP, Lanier LL. IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection. J Immunol. (2015) 194:5948\u201352. 10.4049/jimmunol.1500424", "ArticleIdList": ["10.4049/jimmunol.1500424", "PMC4458425", "25926677"]}, {"Citation": "Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol. (2011) 89:383\u201392. 10.1189/jlb.0810470", "ArticleIdList": ["10.1189/jlb.0810470", "20952658"]}, {"Citation": "Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. (2008) 223:20\u201338. 10.1111/j.1600-065X.2008.00624.x", "ArticleIdList": ["10.1111/j.1600-065X.2008.00624.x", "18613828"]}, {"Citation": "Pushparaj PN, Tay HK, H'Ng S C, Pitman N, Xu D, McKenzie A, et al. . The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. (2009) 106:9773\u20138. 10.1073/pnas.0901206106", "ArticleIdList": ["10.1073/pnas.0901206106", "PMC2700978", "19506243"]}, {"Citation": "Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy. (2010) 40:200\u20138. 10.1111/j.1365-2222.2009.03384.x", "ArticleIdList": ["10.1111/j.1365-2222.2009.03384.x", "19906013"]}, {"Citation": "Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. (2007) 37:2779\u201386. 10.1002/eji.200737547", "ArticleIdList": ["10.1002/eji.200737547", "17853410"]}, {"Citation": "Savenije OE, Mahachie John JM, Granell R, Kerkhof M, Dijk FN, de Jongste JC, et al. . Association of IL33-IL-1 receptor-like 1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood. J Allergy Clin Immunol. (2014) 134:170\u20137. 10.1016/j.jaci.2013.12.1080", "ArticleIdList": ["10.1016/j.jaci.2013.12.1080", "24568840"]}, {"Citation": "Makrinioti H, Toussaint M, Jackson DJ, Walton RP, Johnston SL. Role of interleukin 33 in respiratory allergy and asthma. Lancet Respir Med. (2014) 2:226\u201337. 10.1016/S2213-2600(13)70261-3", "ArticleIdList": ["10.1016/S2213-2600(13)70261-3", "24621684"]}, {"Citation": "Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. . A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. (2010) 363:1211\u201321. 10.1056/NEJMoa0906312", "ArticleIdList": ["10.1056/NEJMoa0906312", "PMC4260321", "20860503"]}, {"Citation": "Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE, et al. . Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet. (2011) 43:887\u201392. 10.1038/ng.888", "ArticleIdList": ["10.1038/ng.888", "PMC3445408", "21804549"]}, {"Citation": "Molofsky AB, Savage AK, Locksley RM. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity. (2015) 42:1005\u201319. 10.1016/j.immuni.2015.06.006", "ArticleIdList": ["10.1016/j.immuni.2015.06.006", "PMC4471869", "26084021"]}, {"Citation": "Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, et al. . Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun. (2015) 6:8327. 10.1038/ncomms9327", "ArticleIdList": ["10.1038/ncomms9327", "PMC4579851", "26365875"]}, {"Citation": "Morita H, Nakae S, Saito H, Matsumoto K. IL-33 in clinical practice: size matters? J Allergy Clin Immunol. (2017) 140:381\u20133. 10.1016/j.jaci.2017.03.042", "ArticleIdList": ["10.1016/j.jaci.2017.03.042", "28478050"]}, {"Citation": "Cayrol C, Duval A, Schmitt P, Roga S, Camus M, Stella A, et al. . Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33. Nat Immunol. (2018) 19:375\u201385. 10.1038/s41590-018-0067-5", "ArticleIdList": ["10.1038/s41590-018-0067-5", "29556000"]}, {"Citation": "Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. . Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. (2009) 31:84\u201398. 10.1016/j.immuni.2009.05.007", "ArticleIdList": ["10.1016/j.immuni.2009.05.007", "19559631"]}, {"Citation": "Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al. . Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. (2008) 20:791\u2013800. 10.1093/intimm/dxn037", "ArticleIdList": ["10.1093/intimm/dxn037", "18448455"]}, {"Citation": "Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, et al. . IL-33 and its receptor ST2 after inhaled allergen challenge in allergic asthmatics. Int Arch Allergy Immunol. (2018) 176:133\u201342. 10.1159/000488015", "ArticleIdList": ["10.1159/000488015", "29694974"]}, {"Citation": "Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. (2008) 121:1484\u201390. 10.1016/j.jaci.2008.04.005", "ArticleIdList": ["10.1016/j.jaci.2008.04.005", "PMC2821937", "18539196"]}, {"Citation": "Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, et al. . Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest. (2008) 88:1245\u201353. 10.1038/labinvest.2008.82", "ArticleIdList": ["10.1038/labinvest.2008.82", "18762778"]}, {"Citation": "Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, et al. . Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet. (2009) 41:342\u20137. 10.1038/ng.323", "ArticleIdList": ["10.1038/ng.323", "19198610"]}, {"Citation": "Wong CK, Cheung PF, Lam CW. Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation. Eur J Immunol. (2007) 37:2337\u201348. 10.1002/eji.200636866", "ArticleIdList": ["10.1002/eji.200636866", "17634954"]}, {"Citation": "Ip WK, Wong CK, Li ML, Li PW, Cheung PF, Lam CW. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology. (2007) 122:532\u201341. 10.1111/j.1365-2567.2007.02668.x", "ArticleIdList": ["10.1111/j.1365-2567.2007.02668.x", "PMC2266039", "17627770"]}, {"Citation": "Leung TF, Wong KY, Wong CK, Fung KP, Lam CW, Fok TF, et al. . In vitro and clinical immunomodulatory effects of a novel Pentaherbs concoction for atopic dermatitis. Br J Dermatol. (2008) 158:1216\u201323. 10.1111/j.1365-2133.2008.08502.x", "ArticleIdList": ["10.1111/j.1365-2133.2008.08502.x", "18341655"]}, {"Citation": "Wong CK, Ng SS, Lun SW, Cao J, Lam CW. Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation. Immunology. (2009) 126:579\u201387. 10.1111/j.1365-2567.2008.02916.x", "ArticleIdList": ["10.1111/j.1365-2567.2008.02916.x", "PMC2673369", "18771439"]}, {"Citation": "Chow JY, Wong CK, Cheung PF, Lam CW. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol. (2010) 7:26\u201334. 10.1038/cmi.2009.106", "ArticleIdList": ["10.1038/cmi.2009.106", "PMC4003257", "20029461"]}, {"Citation": "Wong CK, Leung KM, Qiu HN, Chow JY, Choi AO, Lam CW. Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS ONE. (2012) 7:e29815. 10.1371/journal.pone.0029815", "ArticleIdList": ["10.1371/journal.pone.0029815", "PMC3260155", "22272250"]}, {"Citation": "Liu KY, Hu S, Chan BC, Wat EC, Lau CB, Hon KL, et al. . Anti-inflammatory and anti-allergic activities of Pentaherb formula, Moutan Cortex (Danpi) and gallic acid. Molecules. (2013) 18:2483\u2013500. 10.3390/molecules18032483", "ArticleIdList": ["10.3390/molecules18032483", "PMC6270292", "23439564"]}, {"Citation": "Jiao D, Wong CK, Qiu HN, Dong J, Cai Z, Chu M, et al. . NOD2 and TLR2 ligands trigger the activation of basophils and eosinophils by interacting with dermal fibroblasts in atopic dermatitis-like skin inflammation. Cell Mol Immunol. (2016) 13:535\u201350. 10.1038/cmi.2015.77", "ArticleIdList": ["10.1038/cmi.2015.77", "PMC4947824", "26388234"]}, {"Citation": "Cheung PF, Wong CK, Ho AW, Hu S, Chen DP, Lam CW. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. (2010) 22:453\u201367. 10.1093/intimm/dxq027", "ArticleIdList": ["10.1093/intimm/dxq027", "20410259"]}, {"Citation": "Chen CC, Kobayashi T, Iijima K, Hsu FC, Kita H. IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs. J Allergy Clin Immunol. (2017) 140:1351\u201363.e7. 10.1016/j.jaci.2017.01.015", "ArticleIdList": ["10.1016/j.jaci.2017.01.015", "PMC5554091", "28196763"]}, {"Citation": "Baumann C, Bonilla WV, Frohlich A, Helmstetter C, Peine M, Hegazy AN, et al. . T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci USA. (2015) 112:4056\u201361. 10.1073/pnas.1418549112", "ArticleIdList": ["10.1073/pnas.1418549112", "PMC4386370", "25829541"]}, {"Citation": "Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al. . Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. (2014) 40:425\u201335. 10.1016/j.immuni.2014.01.011", "ArticleIdList": ["10.1016/j.immuni.2014.01.011", "PMC4210641", "24613091"]}, {"Citation": "Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM, et al. . MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity. (2014) 41:283\u201395. 10.1016/j.immuni.2014.06.016", "ArticleIdList": ["10.1016/j.immuni.2014.06.016", "PMC4148706", "25088770"]}, {"Citation": "Hirahara K, Mato N, Hagiwara K, Nakayama T. The pathogenicity of IL-33 on steroid-resistant eosinophilic inflammation via the activation of memory-type ST2(+) CD4(+) T cells. J Leukoc Biol. (2018) 104:895\u2013901. 10.1002/JLB.MR1117-456R", "ArticleIdList": ["10.1002/JLB.MR1117-456R", "29709067"]}, {"Citation": "Drake LY, Kita H. Group 2 innate lymphoid cells in the lung. Adv Immunol. (2014) 124:1\u201316. 10.1016/B978-0-12-800147-9.00001-7", "ArticleIdList": ["10.1016/B978-0-12-800147-9.00001-7", "PMC4449733", "25175771"]}, {"Citation": "Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, et al. . Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature. (2015) 519:242\u20136. 10.1038/nature14115", "ArticleIdList": ["10.1038/nature14115", "PMC4447235", "25533952"]}, {"Citation": "Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol. (2013) 132:205\u201313. 10.1016/j.jaci.2013.03.048", "ArticleIdList": ["10.1016/j.jaci.2013.03.048", "PMC3704056", "23688412"]}, {"Citation": "Liu T, Barrett NA, Kanaoka Y, Yoshimoto E, Garofalo D, Cirka H, et al. . Type 2 Cysteinyl leukotriene receptors drive IL-33-dependent type 2 immunopathology and aspirin sensitivity. J Immunol. (2018) 200:915\u201327. 10.4049/jimmunol.1700603", "ArticleIdList": ["10.4049/jimmunol.1700603", "PMC5780246", "29282304"]}, {"Citation": "Yazdani R, Sharifi M, Shirvan AS, Azizi G, Ganjalikhani-Hakemi M. Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update). Cell Immunol. (2015) 298:66\u201376. 10.1016/j.cellimm.2015.09.006", "ArticleIdList": ["10.1016/j.cellimm.2015.09.006", "26429626"]}, {"Citation": "Lund S, Walford HH, Doherty TA. Type 2 innate lymphoid cells in allergic disease. Curr Immunol Rev. (2013) 9:214\u201321. 10.2174/1573395510666140304235916", "ArticleIdList": ["10.2174/1573395510666140304235916", "PMC4033554", "24876829"]}, {"Citation": "Johansson K, Malmhall C, Ramos-Ramirez P, Radinger M. Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia. Immunology. (2018) 153:268\u201378. 10.1111/imm.12842", "ArticleIdList": ["10.1111/imm.12842", "PMC5765380", "28921511"]}, {"Citation": "Yu Y, Blokhuis BR, Garssen J, Redegeld FA. Non-IgE mediated mast cell activation. Eur J Pharmacol. (2016) 778:33\u201343. 10.1016/j.ejphar.2015.07.017", "ArticleIdList": ["10.1016/j.ejphar.2015.07.017", "26164792"]}, {"Citation": "Jang TY, Kim YH. Interleukin-33 and mast cells bridge innate and adaptive immunity: from the allergologist's perspective. Int Neurourol J. (2015) 19:142\u201350. 10.5213/inj.2015.19.3.142", "ArticleIdList": ["10.5213/inj.2015.19.3.142", "PMC4582085", "26620895"]}, {"Citation": "Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. (2018) 282:121\u201350. 10.1111/imr.12634", "ArticleIdList": ["10.1111/imr.12634", "PMC5813811", "29431212"]}, {"Citation": "Caughey GH. Mast cell proteases as pharmacological targets. Eur J Pharmacol. (2016) 778:44\u201355. 10.1016/j.ejphar.2015.04.045", "ArticleIdList": ["10.1016/j.ejphar.2015.04.045", "PMC4636979", "25958181"]}, {"Citation": "Roy A, Ganesh G, Sippola H, Bolin S, Sawesi O, Dagalv A, et al. . Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. J Biol Chem. (2014) 289:237\u201350. 10.1074/jbc.M112.435156", "ArticleIdList": ["10.1074/jbc.M112.435156", "PMC3879547", "24257755"]}, {"Citation": "Galand C, Leyva-Castillo JM, Yoon J, Han A, Lee MS, McKenzie ANJ, et al. . IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells. J Allergy Clin Immunol. (2016) 138:1356\u201366. 10.1016/j.jaci.2016.03.056", "ArticleIdList": ["10.1016/j.jaci.2016.03.056", "PMC5099088", "27372570"]}, {"Citation": "Zoltowska AM, Lei Y, Fuchs B, Rask C, Adner M, Nilsson GP. The interleukin-33 receptor ST2 is important for the development of peripheral airway hyperresponsiveness and inflammation in a house dust mite mouse model of asthma. Clin Exp Allergy. (2016) 46:479\u201390. 10.1111/cea.12683", "ArticleIdList": ["10.1111/cea.12683", "26609909"]}, {"Citation": "Liu T, Kanaoka Y, Barrett NA, Feng C, Garofalo D, Lai J, et al. . Aspirin-exacerbated respiratory disease involves a Cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol. (2015) 195:3537\u201345. 10.4049/jimmunol.1500905", "ArticleIdList": ["10.4049/jimmunol.1500905", "PMC4592820", "26342029"]}, {"Citation": "Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. J Allergy Clin Immunol. (2018) 142:381\u201393 10.1016/j.jaci.2018.01.034", "ArticleIdList": ["10.1016/j.jaci.2018.01.034", "29454835"]}, {"Citation": "Bandara G, Beaven MA, Olivera A, Gilfillan AM, Metcalfe DD. Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33. Eur J Immunol. (2015) 45:3034\u201344. 10.1002/eji.201545501", "ArticleIdList": ["10.1002/eji.201545501", "PMC4813659", "26256265"]}, {"Citation": "Wang JX, Kaieda S, Ameri S, Fishgal N, Dwyer D, Dellinger A, et al. . IL-33/ST2 axis promotes mast cell survival via BCLXL. Proc Natl Acad Sci USA. (2014) 111:10281\u20136. 10.1073/pnas.1404182111", "ArticleIdList": ["10.1073/pnas.1404182111", "PMC4104908", "24982172"]}, {"Citation": "Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz-Scroggins ME, Peters MC, et al. . Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proc Natl Acad Sci USA. (2016) 113:8765\u201370. 10.1073/pnas.1601914113", "ArticleIdList": ["10.1073/pnas.1601914113", "PMC4978244", "27432971"]}, {"Citation": "Fu Z, Thorpe M, Alemayehu R, Roy A, Kervinen J, de Garavilla L, et al. . Highly Selective cleavage of cytokines and chemokines by the human mast cell chymase and neutrophil cathepsin G. J Immunol. (2017) 198:1474\u201383. 10.4049/jimmunol.1601223", "ArticleIdList": ["10.4049/jimmunol.1601223", "28053237"]}, {"Citation": "Waern I, Jonasson S, Hjoberg J, Bucht A, Abrink M, Pejler G, et al. . Mouse mast cell protease 4 is the major chymase in murine airways and has a protective role in allergic airway inflammation. J Immunol. (2009) 183:6369\u201376. 10.4049/jimmunol.0900180", "ArticleIdList": ["10.4049/jimmunol.0900180", "19841188"]}, {"Citation": "Jogie-Brahim S, Min HK, Fukuoka Y, Xia HZ, Schwartz LB. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol. (2004) 113:1086\u201392. 10.1016/j.jaci.2004.02.032", "ArticleIdList": ["10.1016/j.jaci.2004.02.032", "15208589"]}, {"Citation": "Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol. (2009) 86:769\u201378. 10.1189/jlb.0708452", "ArticleIdList": ["10.1189/jlb.0708452", "PMC2752018", "19451398"]}, {"Citation": "Locksley RM. Asthma and allergic inflammation. Cell. (2010) 140:777\u201383. 10.1016/j.cell.2010.03.004", "ArticleIdList": ["10.1016/j.cell.2010.03.004", "PMC3134388", "20303868"]}, {"Citation": "Melgert BN, ten Hacken NH, Rutgers B, Timens W, Postma DS, Hylkema MN. More alternative activation of macrophages in lungs of asthmatic patients. J Allergy Clin Immunol. (2011) 127:831\u20133. 10.1016/j.jaci.2010.10.045", "ArticleIdList": ["10.1016/j.jaci.2010.10.045", "21167569"]}, {"Citation": "Lee YG, Jeong JJ, Nyenhuis S, Berdyshev E, Chung S, Ranjan R, et al. . Recruited alveolar macrophages, in response to airway epithelial-derived monocyte chemoattractant protein 1/CCl2, regulate airway inflammation and remodeling in allergic asthma. Am J Respir Cell Mol Biol. (2015) 52:772\u201384. 10.1165/rcmb.2014-0255OC", "ArticleIdList": ["10.1165/rcmb.2014-0255OC", "PMC4491131", "25360868"]}, {"Citation": "Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, et al. . IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. (2009) 183:6469\u201377. 10.4049/jimmunol.0901575", "ArticleIdList": ["10.4049/jimmunol.0901575", "19841166"]}, {"Citation": "Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM, et al. . IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol. (2009) 183:1446\u201355. 10.4049/jimmunol.0803067", "ArticleIdList": ["10.4049/jimmunol.0803067", "19553541"]}, {"Citation": "de Kleer IM, Kool M, de Bruijn MJ, Willart M, van Moorleghem J, Schuijs MJ, et al. . Perinatal activation of the interleukin-33 pathway promotes type 2 immunity in the developing lung. Immunity. (2016) 45:1285\u201398. 10.1016/j.immuni.2016.10.031", "ArticleIdList": ["10.1016/j.immuni.2016.10.031", "27939673"]}, {"Citation": "Saluzzo S, Gorki AD, Rana BMJ, Martins R, Scanlon S, Starkl P, et al. . First-breath-induced type 2 pathways shape the lung immune environment. Cell Rep. (2017) 18:1893\u2013905. 10.1016/j.celrep.2017.01.071", "ArticleIdList": ["10.1016/j.celrep.2017.01.071", "PMC5329122", "28228256"]}, {"Citation": "Mindt BC, Fritz JH, Duerr CU. Group 2 innate lymphoid cells in pulmonary immunity and tissue homeostasis. Front Immunol. (2018) 9:840. 10.3389/fimmu.2018.00840", "ArticleIdList": ["10.3389/fimmu.2018.00840", "PMC5937028", "29760695"]}, {"Citation": "Teufelberger AR, Nordengrun M, Braun H, Maes T, De Grove K, Holtappels G, et al. . The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D. J Allergy Clin Immunol. (2018) 141:549\u201359.e7. 10.1016/j.jaci.2017.05.004", "ArticleIdList": ["10.1016/j.jaci.2017.05.004", "28532656"]}, {"Citation": "Liu B, Tai Y, Achanta S, Kaelberer MM, Caceres AI, Shao X, et al. . IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy. Proc Natl Acad Sci USA. (2016) 113:E7572\u20139. 10.1073/pnas.1606608113", "ArticleIdList": ["10.1073/pnas.1606608113", "PMC5127381", "27821781"]}, {"Citation": "Han P, Zhao J, Liu SB, Yang CJ, Wang YQ, Wu GC, et al. . Interleukin-33 mediates formalin-induced inflammatory pain in mice. Neuroscience. (2013) 241:59\u201366. 10.1016/j.neuroscience.2013.03.019", "ArticleIdList": ["10.1016/j.neuroscience.2013.03.019", "23523996"]}, {"Citation": "Kotlyar DS, Shum M, Hsieh J, Blonski W, Greenwald DA. Non-pulmonary allergic diseases and inflammatory bowel disease: a qualitative review. World J Gastroenterol. (2014) 20:11023\u201332. 10.3748/wjg.v20.i32.11023", "ArticleIdList": ["10.3748/wjg.v20.i32.11023", "PMC4145746", "25170192"]}, {"Citation": "Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett. (2010) 128:80\u20135. 10.1016/j.imlet.2009.11.001", "ArticleIdList": ["10.1016/j.imlet.2009.11.001", "19913053"]}, {"Citation": "Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C, et al. . Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. (2010) 16:1097\u2013107. 10.1002/ibd.21175", "ArticleIdList": ["10.1002/ibd.21175", "20014018"]}, {"Citation": "Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, et al. . Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA. (2010) 107:8017\u201322. 10.1073/pnas.0912678107", "ArticleIdList": ["10.1073/pnas.0912678107", "PMC2867895", "20385815"]}, {"Citation": "Sponheim J, Pollheimer J, Olsen T, Balogh J, Hammarstrom C, Loos T, et al. . Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol. (2010) 177:2804\u201315. 10.2353/ajpath.2010.100378", "ArticleIdList": ["10.2353/ajpath.2010.100378", "PMC2993251", "21037074"]}, {"Citation": "Nunes T, Bernardazzi C, de Souza HS. Interleukin-33 and inflammatory bowel diseases: lessons from human studies. Mediators Inflamm. (2014) 2014:423957. 10.1155/2014/423957", "ArticleIdList": ["10.1155/2014/423957", "PMC3950548", "24701033"]}, {"Citation": "Tu L, Chen J, Xu D, Xie Z, Yu B, Tao Y, et al. . IL-33-induced alternatively activated macrophage attenuates the development of TNBS-induced colitis. Oncotarget. (2017) 8:27704\u201314. 10.18632/oncotarget.15984", "ArticleIdList": ["10.18632/oncotarget.15984", "PMC5438602", "28423665"]}, {"Citation": "Vocca L, Di Sano C, Uasuf CG, Sala A, Riccobono L, Gangemi S, et al. . IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology. (2015) 220:954\u201363. 10.1016/j.imbio.2015.02.005", "ArticleIdList": ["10.1016/j.imbio.2015.02.005", "25747940"]}, {"Citation": "Fattori V, Borghi SM, Verri WA, Jr. IL-33/ST2 signaling boosts inflammation and pain. Proc Natl Acad Sci USA. (2017) 114:E10034\u20135. 10.1073/pnas.1716120114", "ArticleIdList": ["10.1073/pnas.1716120114", "PMC5703330", "29109297"]}, {"Citation": "Khaitov MR, Gaisina AR, Shilovskiy IP, Smirnov VV, Ramenskaia GV, Nikonova AA, et al. . The role of interleukin-33 in pathogenesis of bronchial asthma. New experimental data. Biochemistry. (2018) 83:13\u201325. 10.1134/S0006297918010029", "ArticleIdList": ["10.1134/S0006297918010029", "29534664"]}, {"Citation": "Johnston LK, Hsu CL, Krier-Burris RA, Chhiba KD, Chien KB, McKenzie A, et al. . IL-33 precedes IL-5 in regulating eosinophil commitment and is required for eosinophil homeostasis. J Immunol. (2016) 197:3445\u201353. 10.4049/jimmunol.1600611", "ArticleIdList": ["10.4049/jimmunol.1600611", "PMC5101160", "27683753"]}, {"Citation": "Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, et al. . IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol. (2013) 132:676\u201385.e13. 10.1016/j.jaci.2013.04.012", "ArticleIdList": ["10.1016/j.jaci.2013.04.012", "PMC4218948", "23759184"]}, {"Citation": "Balato A, Di Caprio R, Canta L, Mattii M, Lembo S, Raimondo A, et al. . IL-33 is regulated by TNF-alpha in normal and psoriatic skin. Arch Dermatol Res. (2014) 306:299\u2013304. 10.1007/s00403-014-1447-9", "ArticleIdList": ["10.1007/s00403-014-1447-9", "24522896"]}, {"Citation": "Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, et al. . Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. (2010) 45:999\u20131007. 10.1007/s00535-010-0245-1", "ArticleIdList": ["10.1007/s00535-010-0245-1", "20405148"]}, {"Citation": "Yanagawa Y, Matsumoto M, Togashi H. Adrenoceptor-mediated enhancement of interleukin-33 production by dendritic cells. Brain Behav Immun. (2011) 25:1427\u201333. 10.1016/j.bbi.2011.04.012", "ArticleIdList": ["10.1016/j.bbi.2011.04.012", "21536121"]}, {"Citation": "Nabe T. Interleukin (IL)-33: new therapeutic target for atopic diseases. J Pharmacol Sci. (2014) 126:85\u201391. 10.1254/jphs.14R12CP", "ArticleIdList": ["10.1254/jphs.14R12CP", "25213717"]}, {"Citation": "Thio CL, Chi PY, Lai AC, Chang YJ. Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate. J Allergy Clin Immunol. (2018) 142:1867\u201383.e12. 10.1016/j.jaci.2018.02.032", "ArticleIdList": ["10.1016/j.jaci.2018.02.032", "29522844"]}, {"Citation": "Kouzaki H, Matsumoto K, Kikuoka H, Kato T, Tojima I, Shimizu S, et al. . Endogenous protease inhibitors in airway epithelial cells contribute to eosinophilic chronic rhinosinusitis. Am J Respir Crit Care Med. (2017) 195:737\u201347. 10.1164/rccm.201603-0529OC", "ArticleIdList": ["10.1164/rccm.201603-0529OC", "PMC5803669", "27779422"]}, {"Citation": "Shen ZJ, Esnault S, Malter JS. The peptidyl-prolyl isomerase Pin1 regulates the stability of granulocyte-macrophage colony-stimulating factor mRNA in activated eosinophils. Nat Immunol. (2005) 6:1280\u20137. 10.1038/ni1266", "ArticleIdList": ["10.1038/ni1266", "16273101"]}, {"Citation": "Nechama M, Kwon J, Wei S, Kyi AT, Welner RS, Ben-Dov IZ, et al. . The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. Nat Commun. (2018) 9:1603. 10.1038/s41467-018-03886-6", "ArticleIdList": ["10.1038/s41467-018-03886-6", "PMC5913134", "29686383"]}, {"Citation": "Li J, Saruta K, Dumouchel JP, Magat JM, Thomas JL, Ajami D, et al. . Small molecule mimetics of alpha-helical domain of IRAK2 attenuate the proinflammatory effects of IL-33 in asthma-like mouse models. J Immunol. (2018) 200:4036\u201343. 10.4049/jimmunol.1700693", "ArticleIdList": ["10.4049/jimmunol.1700693", "PMC5988972", "29728508"]}, {"Citation": "Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. (2010) 465:885\u201390. 10.1038/nature09121", "ArticleIdList": ["10.1038/nature09121", "PMC2888693", "20485341"]}, {"Citation": "Park CS, Jang TY, Heo MJ, Jung AY, Kim YH. Antiallergic effects of anti-interleukin-33 are associated with suppression of immunoglobulin light chain and inducible nitric oxide synthase. Am J Rhinol Allergy. (2016) 30:17\u201322. 10.2500/ajra.2015.29.4251", "ArticleIdList": ["10.2500/ajra.2015.29.4251", "26489077"]}, {"Citation": "Fursov N, Lu J, Healy C, Wu SJ, Lacy E, Filer A, et al. . Monoclonal antibodies targeting ST2L Domain 1 or Domain 3 differentially modulate IL-33-induced cytokine release by human mast cell and basophilic cell lines. Mol Immunol. (2016) 75:178\u201387. 10.1016/j.molimm.2016.05.019", "ArticleIdList": ["10.1016/j.molimm.2016.05.019", "27294560"]}, {"Citation": "Ohta K, Nagase H, Suzukawa M, Ohta S. Antibody therapy for the management of severe asthma with eosinophilic inflammation. Int Immunol. (2017) 29:337\u201343. 10.1093/intimm/dxx045", "ArticleIdList": ["10.1093/intimm/dxx045", "28910970"]}, {"Citation": "Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. . Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract. (2017) 5:S1\u201314. 10.1016/j.jaip.2016.11.029", "ArticleIdList": ["10.1016/j.jaip.2016.11.029", "28143691"]}, {"Citation": "Hodzic Z, Schill EM, Bolock AM, Good M. IL-33 and the intestine: the good, the bad, and the inflammatory. Cytokine. (2017) 100:1\u201310. 10.1016/j.cyto.2017.06.017", "ArticleIdList": ["10.1016/j.cyto.2017.06.017", "PMC5650929", "28687373"]}, {"Citation": "Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. (2010) 9:325\u201338. 10.1038/nrd3003", "ArticleIdList": ["10.1038/nrd3003", "20305665"]}, {"Citation": "Liu L, Li Y. The unexpected side effects and safety of therapeutic monoclonal antibodies. Drugs Today. (2014) 50:33\u201350. 10.1358/dot.2014.50.1.2076506", "ArticleIdList": ["10.1358/dot.2014.50.1.2076506", "24524104"]}, {"Citation": "Jeon WY, Shin HK, Shin IS, Kim SK, Lee MY. Soshiho-tang water extract inhibits ovalbumin-induced airway inflammation via the regulation of heme oxygenase-1. BMC Complement Altern Med. (2015) 15:329. 10.1186/s12906-015-0857-3", "ArticleIdList": ["10.1186/s12906-015-0857-3", "PMC4575434", "26385707"]}, {"Citation": "Ohtake N, Nakai Y, Yamamoto M, Ishige A, Sasaki H, Fukuda K, et al. . The herbal medicine Shosaiko-to exerts different modulating effects on lung local immune responses among mouse strains. Int Immunopharmacol. (2002) 2:357\u201366. 10.1016/S1567-5769(01)00161-8", "ArticleIdList": ["10.1016/S1567-5769(01)00161-8", "11811938"]}, {"Citation": "Chen M, Ding P, Yang L, He X, Gao C, Yang G, et al. . Evaluation of anti-inflammatory activities of Qingre-Qushi Recipe (QRQS) against atopic dermatitis: potential mechanism of inhibition of IL-33/ST2 signal transduction. Evid Based Complement Alternat Med. (2017) 2017:2489842. 10.1155/2017/2489842", "ArticleIdList": ["10.1155/2017/2489842", "PMC5511684", "28751921"]}, {"Citation": "Qiu R, Ma G, Zheng C, Qiu X, Li X, Li X, et al. . Antineoplastic effect of calycosin on osteosarcoma through inducing apoptosis showing in vitro and in vivo investigations. Exp Mol Pathol. (2014) 97:17\u201322. 10.1016/j.yexmp.2014.04.014", "ArticleIdList": ["10.1016/j.yexmp.2014.04.014", "24797937"]}, {"Citation": "Tao Y, Wang Y, Wang X, Wang C, Bao K, Ji L, et al. . Calycosin suppresses epithelial derived initiative key factors and maintains epithelial barrier in allergic inflammation via TLR4 mediated NF-kappaB pathway. Cell Physiol Biochem. (2017) 44:1106\u201319. 10.1159/000485416", "ArticleIdList": ["10.1159/000485416", "29179209"]}, {"Citation": "Wang X, Jiang X, Yu X, Liu H, Tao Y, Jiang G, et al. . Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions. J Cell Mol Med. (2017) 21:2926\u201336. 10.1111/jcmm.13204", "ArticleIdList": ["10.1111/jcmm.13204", "PMC5661257", "28597545"]}, {"Citation": "Giangaspero A, Ponti C, Pollastro F, Del Favero G, Della Loggia R, Tubaro A, et al. . Topical anti-inflammatory activity of Eupatilin, a lipophilic flavonoid from mountain wormwood ( Artemisia umbelliformis Lam.). J Agric Food Chem. (2009) 57:7726\u201330. 10.1021/jf901725p", "ArticleIdList": ["10.1021/jf901725p", "19663482"]}, {"Citation": "Jung Y, Kim JC, Choi Y, Lee S, Kang KS, Kim YK, et al. . Eupatilin with PPARalpha agonistic effects inhibits TNFalpha-induced MMP signaling in HaCaT cells. Biochem Biophys Res Commun. (2017) 493:220\u20136. 10.1016/j.bbrc.2017.09.043", "ArticleIdList": ["10.1016/j.bbrc.2017.09.043", "28899779"]}, {"Citation": "Jung Y, Kim JC, Park NJ, Bong SK, Lee S, Jegal H, et al. . Eupatilin, an activator of PPARalpha, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. Biochem Biophys Res Commun. (2018) 496:508\u201314. 10.1016/j.bbrc.2018.01.098", "ArticleIdList": ["10.1016/j.bbrc.2018.01.098", "29353040"]}, {"Citation": "Song Y, Wu Y, Li X, Shen Y, Ding Y, Zhu H, et al. . Protostemonine attenuates alternatively activated macrophage and DRA-induced asthmatic inflammation. Biochem Pharmacol. (2018) 155:198\u2013206. 10.1016/j.bcp.2018.07.003", "ArticleIdList": ["10.1016/j.bcp.2018.07.003", "29991449"]}, {"Citation": "Weng Z, Patel AB, Panagiotidou S, Theoharides TC. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol. (2015) 135:1044\u201352.e5. 10.1016/j.jaci.2014.10.032", "ArticleIdList": ["10.1016/j.jaci.2014.10.032", "PMC4388775", "25498791"]}, {"Citation": "Theoharides TC, Stewart JM, Tsilioni I. Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. Int J Immunopathol Pharmacol. (2017) 30:146\u201351. 10.1177/0394632017707610", "ArticleIdList": ["10.1177/0394632017707610", "PMC5806797", "28480804"]}, {"Citation": "Patel AB, Tsilioni I, Weng Z, Theoharides TC. TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin. Exp Dermatol. (2018) 27:135\u201343. 10.1111/exd.13461", "ArticleIdList": ["10.1111/exd.13461", "29105195"]}, {"Citation": "Tsang MS, Jiao D, Chan BC, Hon KL, Leung PC, Lau CB, et al. . Anti-inflammatory activities of pentaherbs formula, berberine, gallic acid and chlorogenic acid in atopic dermatitis-like skin inflammation. Molecules. (2016) 21:519. 10.3390/molecules21040519", "ArticleIdList": ["10.3390/molecules21040519", "PMC6274171", "27104513"]}, {"Citation": "Chan BC, Li LF, Hu SQ, Wat E, Wong EC, Zhang VX, et al. . Gallic acid is the major active component of cortex moutan in inhibiting immune maturation of human monocyte-derived dendritic cells. Molecules. (2015) 20:16388\u2013403. 10.3390/molecules200916388", "ArticleIdList": ["10.3390/molecules200916388", "PMC6331828", "26378505"]}, {"Citation": "Dong M, Ma C, Wang WQ, Chen J, Wei Y. Regulation of the IL-33/ST2 pathway contributes to the anti-inflammatory effect of acupuncture in the ovalbumin-induced murine asthma model. Acupunct Med. (2018) 36:319\u201326. 10.1136/acupmed-2017-011377", "ArticleIdList": ["10.1136/acupmed-2017-011377", "29581139"]}, {"Citation": "Chen WY, Tsai TH, Yang JL, Li LC. Therapeutic strategies for targeting IL-33/ST2 signalling for the treatment of inflammatory diseases. Cell Physiol Biochem. (2018) 49:349\u201358. 10.1159/000492885", "ArticleIdList": ["10.1159/000492885", "30138941"]}, {"Citation": "Salas A. The IL-33/ST2 axis: yet another therapeutic target in inflammatory bowel disease? Gut. (2013) 62:1392\u20133. 10.1136/gutjnl-2012-303920", "ArticleIdList": ["10.1136/gutjnl-2012-303920", "23315502"]}, {"Citation": "Alves MF, da Fonseca DV, de Melo SA L, Scotti MT, Scotti L, Dos Santos SG, et al. . New therapeutic targets and drugs for the treatment of asthma. Mini Rev Med Chem. (2018) 18:684\u201396. 10.2174/1389557517666170927145011", "ArticleIdList": ["10.2174/1389557517666170927145011", "28971769"]}, {"Citation": "Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol. (2017) 8:475. 10.3389/fimmu.2017.00475", "ArticleIdList": ["10.3389/fimmu.2017.00475", "PMC5402045", "28484466"]}]}], "History": [{"Year": "2018", "Month": "5", "Day": "18"}, {"Year": "2019", "Month": "2", "Day": "12"}, {"Year": "2019", "Month": "3", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "3", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "9", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["30886621", "PMC6409346", "10.3389/fimmu.2019.00364"]}}]}